Palisade Bio (PALI) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palisade Bio (PALI) has outperformed X4 Pharmaceuticals (XFOR) over the past year, losing 11.9% versus a loss of 18.3%. Over five years, XFOR leads with a -98.2% price change compared with -99.9% for PALI. X4 Pharmaceuticals is the larger company by market cap ($269.2 million vs $242.0 million), about 1.1 times the size.
On valuation, Palisade Bio trades at a lower trailing P/E (2.3x vs 135.8x for X4 Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PALI | XFOR |
|---|---|---|
| Share price | $1.39 | $2.72 |
| Market cap | $242.03M | $269.18M |
| 1-day change | -6.16% | -3.38% |
| YTD return | -37.02% | -29.75% |
| 1-year return | -11.90% | -18.31% |
| 5-year return | -99.93% | -98.21% |
| P/E ratio (TTM) | 2.31 | 135.75 |
| EPS (TTM) | $0.60 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.86 | $4.83 |
| 52-week low | $1.32 | $2.70 |
| Distance from 52-week high | -51.44% | -43.79% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +635.89% | +327.26% |
| Average volume | 2.60M | 843.50K |
| Shares outstanding | 174.27M | 99.15M |
| Employees | 14 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- X4 Pharmaceuticals trades at a higher earnings multiple (135.8x vs 2.3x trailing P/E).
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
PALI vs XFOR FAQ
Which is bigger, Palisade Bio or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $269.18M compared with $242.03M for Palisade Bio (PALI).
Which stock has performed better over the past year, PALI or XFOR?
PALI returned -11.90% over the past 12 months, compared with -18.31% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PALI or XFOR?
PALI has the lower trailing P/E at 2.3, versus 135.8 for XFOR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Palisade Bio and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.